17 recruiting, 11 active not recruiting, 8 completed, 7 unknown. 30 Phase 1, 23 Phase 2, 3 Not applicable.
Follow High-grade B-cell Lymphoma: new trials by email Literature Review of High-grade B-cell Lymphoma trials Research Report on High-grade B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2) - Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 39 | 2026-08-20 | 2026-08-19 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-08-06 |
| Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Recruiting | Fondazione Italiana Linfomi - ETS | 200 | 2025-05-05 | 2025-12-29 | |
| CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | British Columbia Cancer Agency | 24 | 2025-01-02 | 2026-10-14 |
| A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma Cerebral Spinal Fluid ctDNA - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2024-12-11 | 2025-12-18 |
| ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment - Lymphoma, Lymphoma, B-Cell | Not applicable | Recruiting | Hua-Jay J Cherng, MD | 40 | 2024-12-11 | 2026-01-23 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Epcoritamab-CAR T Cells for Large B-cell Lymphomas Epcoritamab - Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 31 | 2024-09-24 | 2026-05-27 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) Adaptive Bridging Radiation Therapy (ABRT) - Lymphoma, B-Cell, Relapsed Cancer | Not applicable | Completed | Massachusetts General Hospital | 10 | 2024-01-14 | 2026-10-15 |
| Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL Epcoritamab - DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Recruiting | Australasian Leukaemia and Lymphoma Group | 39 | 2023-12-11 | 2024-07-22 |
| Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B | Phase 2 | Active not recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 46 | 2023-11-03 | 2025-02-11 |
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 24 | 2023-10-26 | 2026-10-09 |
| Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS) - Lymphoma, B-Cell, Neoplasms | Unknown | Sociedad de Lucha Contra el Cáncer del Ecuador | 50 | 2023-09-01 | 2023-06-22 | |
| A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) Loncastuximab Tesirine - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | ADC Therapeutics S.A. | 5 | 2023-07-28 | 2026-07-20 |
Showing 20 of 52. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (41) · Lymphoma, Follicular (18) · Lymphoma, Non-Hodgkin (18) · Lymphoma, B-Cell (16) · Lymphoma, Mantle-Cell (10) · Burkitt Lymphoma (9) · Lymphoma (9) · Lymphoma, B-Cell, Marginal Zone (9) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Recurrence (6) · Dendritic Cell Sarcoma, Interdigitating (5) · Pyloric Stenosis, Hypertrophic (5) · Lymphoma, Primary Effusion (2) · Lymphoma, T-Cell, Peripheral (2) · Waldenstrom Macroglobulinemia (2)
Hemic and Lymphatic Diseases (49) · Immune System Diseases (49) · Immunoproliferative Disorders (49) · Lymphoproliferative Disorders (49) · Neoplasms by Histologic Type (49) · Lymphatic Diseases (48) · Neoplasms (48) · Lymphoma (40) · Lymphoma, B-Cell (31) · Lymphoma, Non-Hodgkin (31) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Disease Attributes (12) · DNA Virus Infections (9) · Epstein-Barr Virus Infections (9)
Cyclophosphamide (14) · Rituximab (10) · Doxorubicin (6) · fludarabine (6) · Vincristine (5) · Prednisone (4) · Lenalidomide (3) · R-CHOP protocol (3) · axicabtagene ciloleucel (3) · glofitamab (3) · obinutuzumab (3) · polatuzumab vedotin (3) · Dexamethasone (2) · Etoposide (2) · Gemcitabine (2)
Huiqiang Huang (3) · Genmab (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Marcela V. Maus, M.D.,Ph.D. (2) · Masonic Cancer Center, University of Minnesota (2) · Memorial Sloan Kettering Cancer Center (2) · Washington University School of Medicine (2) · ADC Therapeutics S.A. (1) · Abramson Cancer Center at Penn Medicine (1) · Acepodia Biotech, Inc. (1) · AstraZeneca (1) · Australasian Leukaemia and Lymphoma Group (1) · Barbara Ann Karmanos Cancer Institute (1) · British Columbia Cancer Agency (1) · Brown University (1)
United States (31) · China (8) · South Korea (5) · Australia (4) · Taiwan (4) · Spain (3) · Belgium (2) · Denmark (2) · Italy (2) · Japan (2) · Netherlands (2) · United Kingdom (2) · Brazil (1) · Canada (1) · Ecuador (1)
Matthew Frigault, MD (2) · Adam Olszewski (1) · Ann LaCasce, MD (1) · Armin Ghobadi, M.D. (1) · Caspian Oliai, MD (1) · Chirayu Patel, MD (1) · Christopher R D'Angelo, MD (1) · Daniel Hodson, PhD MRCP FRCPath (1) · David Russler-Germain, M.D., Ph.D. (1) · David Sermer, MD (1) · Dehui Zou, Dr. (1) · Depei Wu, PhD (1) · Dipenkumar Modi, M.D. (1) · Dr.Veronika Bachanova, MD, PhD (1)
PMID 34581757, PMID 34628052, PMID 35332334, PMID 38022532, PMID 39319495, PMID 40178467, PMID 40532125, PMID 40632620, PMID 42284198, PMID 42411504, PMID 42541678
2017 (2), 2019 (1), P01CA111412 (1), P30CA022453 (1), R03CA286676 (1)